Some T cell subsets, including interleukin-17–producing T cells have been shown to play a role in rheumatoid arthritis (RA), and the interleukin-17 (IL-17) pathway is a current therapeutic target in the condition [20–23]. Here, IL17A is linked to rheumatoid arthritis.